PRKCD and acute myeloid leukemia: These subtypes support findings reported in other AML cohorts, such as the increased phosphorylation of PRKCD observed in subtype 4, which was also identified in an independent AML proteomics cohort53,54,55 and increased mitochondrial activity, oxidative phosphorylation, and poor overall survival in subtype 2, which aligns with the c-mito subtype identified by Jayavelu et al.